When GI upset strikes, it's often a sign of a simple stomachache. But when the issue becomes more recurrent, it can be a question of IBD vs. IBS. Irritable bowel syndrome (IBS) affects between 25 and ...

Standing in a muddy field at Glastonbury, Tom Dawson realised something wasn’t right. Although bowel disease wasn’t top of his mind as he watched his favourite bands, he couldn’t dismiss the urgent ...

It can be overwhelming to receive a diagnosis of inflammatory bowel disease (IBD), a condition which refers to the chronic diseases that can cause inflammation in your gastrointestinal (GI) tract.

Adjunct therapies like the Mediterranean diet, exercise, and CBT can improve quality of life for IBS and IBD patients by reducing persistent digestive symptoms. Despite standard drug treatments, many ...

It may not be something you like to talk about, but if you have gastrointestinal (GI) problems, your symptoms may be far more common than you think. According to data from the American ...

LAS VEGAS, Nevada — Low-dose tricyclic antidepressant therapy is effective in treating moderately severe functional symptoms in patients with inflammatory bowel disease (IBD) who are not experiencing ...

Statin use in patients with moderate-to-severe inflammatory bowel disease (IBD) was associated with a 49% lower odds of IBD-related surgery, a retrospective study found. (Inflammatory Bowel Diseases) ...

To understand how other health problems can look like IBD, it helps to understand the differences between the two main types of IBD. For example, while Crohn’s and UC can both cause diarrhea, bleeding ...

A meta-analysis found that antibiotics in childhood were linked to a 42% higher risk for inflammatory bowel disease (IBD), though the researchers expressed caution on the findings. (Inflammatory Bowel ...

Keep in mind, the two diseases are not connected, and having IBS doesn’t increase your risk of colon cancer. However, some cancer treatments can disturb your stomach. Unlike inflammatory bowel disease ...

LONDON--(BUSINESS WIRE)--By 2017 the gastrointestinal disorder therapeutics market is expected to be worth $18.3 billion by 2017, according to a new report available on companiesandmarkets.com.